author-photo

Kihyun Kim

Samsung Medical Center
Dong-a University

301

Papers

3426

Citations

Citation Trend

Filter By

Papers (213) Sort By

Journal Conference Others

Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis.

2021 Blood Research
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Exploration of the Appropriate NT-Probnp Level for AL Amyloidosis Staging

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT.

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (0)
Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)